Rheumatic Diseases and the Liver

  • Atsushi Takahashi
  • Kazumichi Abe
  • Hiroshi Watanabe
  • Hiromasa Ohira


Rheumatic diseases affect multiple organs, including the liver. Liver dysfunction is not rare in patients with rheumatic diseases. Not only rheumatic disease itself, but also other factors such as drug toxicity, virus, fatty infiltration and overlapping autoimmune liver disease can cause liver dysfunction. Therefore, liver dysfunction in patients with collagen diseases needs to be considered separately from the rheumatic disease itself and other causes. Liver dysfunction in patients with rheumatic disease is tended to be mild and temporary, so the causes are often overlooked. However, acute liver failure occurs infrequently by some causes such as de novo hepatitis B or adult-onset Still’s disease. Liver dysfunction in patients with rheumatic disease shows relatively specific tendencies for each collagen disease. On the other hand, liver dysfunction caused by systemic lupus erythematosus (SLE) itself is difficult to distinguish from autoimmune hepatitis (AIH) because of the laboratory findings are similar. Histological examination of the liver is useful for differentially diagnosing AIH and SLE-associated hepatitis. The feature of liver dysfunction and its causes need to be elucidated and considered when treating rheumatic diseases.


Systemic Lupus Erythematosus Rheumatoid Arthritis Patient Systemic Lupus Erythematosus Patient Liver Dysfunction Nodular Regenerative Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol. 2002;37:617–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123–9.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Malnick S, Melzer E, Sokolowski N, Basevitz A. The involvement of the liver in systemic diseases. J Clin Gastroenterol. 2008;42:69–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Takahashi A, Abe K, Yokokawa J, Iwadate H, Kobayashi H, Watanabe H, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092–7. doi: 10.1111/j.1872-034X.2010.00707.x.PubMedCrossRefGoogle Scholar
  6. 6.
    Schlenker C, Halterman T, Kowdley KV. Rheumatologic disease and the liver. Clin Liver Dis. 2011;15:153–64. doi: 10.1016/j.cld.2010.09.006.PubMedCrossRefGoogle Scholar
  7. 7.
    Ohira H, Abe K, Takahashi A. Involvement of the liver in rheumatic disease. Clin J Gastroenterol. 2012;5:9–14. doi: 10.1007/s12328-011-0271-4.PubMedCrossRefGoogle Scholar
  8. 8.
    Fernandes L, Sullivan S, McFarlane IG, Wojcicka BM, Warnes TW, Eddleston AL, et al. Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis. Ann Rheum Dis. 1979;38:501–6.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Spooner RJ, Smith DH, Bedford D, Beck PR. Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. J Clin Pathol. 1982;35:638–41.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Aida S. Alkaline phosphatase isoenzyme activities in rheumatoid arthritis: hepatobiliary enzyme dissociation and relation to disease activity. Ann Rheum Dis. 1993;52:511–6.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Lowe JR, Pickup ME, Dixon JS, Leatham PA, Rhind VM, Wright V, et al. Gamma glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1978;37:428–31.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Grover S, Rastogi A, Singh J, Rajbongshi A, Bihari C. Spectrum of histomorphologic findings in liver in patients with SLE: a review. Hepat Res Treat. 2014;2014:562979. doi: 10.1155/2014/562979.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Zheng RH, Wang JH, Wang SB, Chen J, Guan WM, Chen MH. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl). 2013;126:260–6.Google Scholar
  14. 14.
    Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med. 1984;53:401–9.PubMedGoogle Scholar
  15. 15.
    Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35:2159–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol. 2010;28:504–10.PubMedGoogle Scholar
  17. 17.
    Huang D, Aghdassi E, Su J, Mosko J, Hirschfield GM, Gladman DD, et al. Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. J Rheumatol. 2012;39:254–61. doi: 10.3899/jrheum.110310.PubMedCrossRefGoogle Scholar
  18. 18.
    Takahashi A, Abe K, Saito R, Iwadate H, Okai K, Katsushima F, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52:1461–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Luangjaru S, Kullavanijaya P. Gastrointestinal and hepatobiliary manifestations in systemic lupus erythematosus. J Med Assoc Thai. 2005;88:71–5.PubMedGoogle Scholar
  21. 21.
    Her M, Lee Y, Jung E, Kim T, Kim D. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int. 2011;31:79–84. doi: 10.1007/s00296-009-1237-4.PubMedCrossRefGoogle Scholar
  22. 22.
    Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythematosus. J Rheumatol. 1981;8:752–9.PubMedGoogle Scholar
  23. 23.
    Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med. 1995;99:465–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Hulsey M, Goldstein R, Scully L, Surbeck W, Reichlin M. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol. 1995;74:252–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Yoshio T, Masuyama JI, Minota S, Kaneko N, Iwamoto M, Okazaki H, et al. A close temporal relationship of liver disease to antiribosomal P0 protein antibodies and central nervous system disease in patients with systemic lupus erythematosus. J Rheumatol. 1998;25:681–8.PubMedGoogle Scholar
  26. 26.
    Ohira H, Takiguchi J, Rai T, Abe K, Yokokawa J, Sato Y, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res. 2004;28:137–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Calich AL, Viana VS, Cancado E, Tustumi F, Terrabuio DR, Leon EP, et al. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int. 2013;33:909–13. doi: 10.1111/liv.12155.PubMedCrossRefGoogle Scholar
  28. 28.
    Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: clues for diagnosis and hints for pathogenesis. World J Hepatol. 2014;6(6):394–409. doi: 10.4254/wjh.v6.i6.394.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Horizon AA, Wallace DJ. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3:273–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16:5651–61.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Zimmerman HJ. Editorial: aspirin-induced hepatic injury. Ann Intern Med. 1974;80:103–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127:303–14. doi: 10.1016/j.jaci.2010.12.1087.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23:225–35. doi: 10.1177/0961203313519159.PubMedCrossRefGoogle Scholar
  34. 34.
    Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275–9.PubMedGoogle Scholar
  35. 35.
    Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum. 2000;43(12):2801–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology. J Viral Hepat. 1997;4 Suppl 2:42–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Watanabe R, Ishii T, Nakamura K, Shirai T, Tajima Y, Fujii H, et al. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy. Mod Rheumatol. 2013;23:1094–100. doi: 10.1007/s10165-012-0797-4.PubMedCrossRefGoogle Scholar
  38. 38.
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. doi: 10.1002/hep.22945.PubMedCrossRefGoogle Scholar
  39. 39.
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMedGoogle Scholar
  40. 40.
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39. doi: 10.1002/acr.21641.CrossRefGoogle Scholar
  41. 41.
    Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24:1–7. doi: 10.3109/14397595.2013.852834.PubMedCrossRefGoogle Scholar
  42. 42.
    Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, Brito-Zerón P, Bertolaccini L, et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine. 2008;87:311–8. doi: 10.1097/MD.0b013e31818ec711.PubMedCrossRefGoogle Scholar
  43. 43.
    Tsai WP, Chen MH, Lee MH, Yu KH, Wu MW, Liou LB. Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol Int. 2012;32(9):2901–8. doi: 10.1007/s00296-011-2131-4.PubMedCrossRefGoogle Scholar
  44. 44.
    Zhang J, Dou Y, Zhong Z, Su J, Xu D, Tang F, et al. Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients. Lupus. 2014;23:889–97.PubMedCrossRefGoogle Scholar
  45. 45.
    Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev. 2004;3:69–75.PubMedCrossRefGoogle Scholar
  48. 48.
    Sekigawa I, Suzuki J, Nawata M, Ikeda K, Koike M, Iida N, et al. Hemophagocytosis in autoimmune disease. Clin Exp Rheumatol. 2001;19:333–8.PubMedGoogle Scholar
  49. 49.
    Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, et al. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol. 2004;14:205–15.PubMedCrossRefGoogle Scholar
  50. 50.
    Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–23.PubMedCrossRefGoogle Scholar
  51. 51.
    Harada K. Autoimmune hepatitis: histological findings of autoimmune hepatitis. In: Ohira H, editor. Autoimmune liver disease. Tokyo: Springer; 2014.Google Scholar
  52. 52.
    Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H, Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–41. doi: 10.1007/s00535-011-0421-y.PubMedCrossRefGoogle Scholar
  53. 53.
    Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol. 2014;20:12662–7. doi: 10.3748/wjg.v20.i35.12662.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Oka H. The survey of autoimmune hepatitis in Japan. Annual report of the Study Group on Severe Hepatitis. Japanese Ministry of Health and Welfare. 1988;235–241 (Japanese).Google Scholar
  56. 56.
    Onder FO, Yürekli OT, Oztaş E, Kalkan IH, Köksal AS, Akdoğan M, et al. Features of systemic lupus erythematosus in patients with autoimmune hepatitis. Rheumatol Int. 2013;33(6):1581–5. doi: 10.1007/s00296-012-2607-x.PubMedCrossRefGoogle Scholar
  57. 57.
    Iwai M, Harada Y, Ishii M, Tanaka S, Muramatsu A, Mori T. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin Rheumatol. 2003;22:234–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.PubMedCrossRefGoogle Scholar
  59. 59.
    Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303–30. doi: 10.1146/annurev-pathol-020712-164014.PubMedCrossRefGoogle Scholar
  60. 60.
    Hirohara J. National surveys of primary biliary cirrhosis (PBC) in Japan. Annual report of the intractable Liver and Biliary Diseases Study Group of Japan. Japanese Ministry of Health, Labour and Welfare. 2013;63–67 (Japanese).Google Scholar
  61. 61.
    Wang L, Zhang FC, Chen H, Zhang X, Xu D, Li YZ, et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol. 2013;19:5131–7. doi: 10.3748/wjg.v19.i31.5131.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004;97:397–406.PubMedCrossRefGoogle Scholar
  63. 63.
    Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis. 2001;60:1046–9.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Saito H, Takahashi A, Abe K, Monoe K, Kanno Y, Yokokawa J, et al. Two cases of primary biliary cirrhosis associated with systemic lupus erythematosus. Kanzo. 2011;52:169–75 (Japanese).CrossRefGoogle Scholar
  65. 65.
    Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–7. doi: 10.1002/hep.22428.PubMedCrossRefGoogle Scholar
  66. 66.
    Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360(24):2544–55. doi: 10.1056/NEJMoa0810440.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41:1234–7. doi: 10.1038/ng.472.PubMedCrossRefGoogle Scholar
  68. 68.
    Akesson A, Berglund K, Karlsson M. Liver function in some common rheumatic disorders. Scand J Rheumatol. 1980;9:81–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Rau R, Pfenninger K, Boni A. Proceedings: liver function tests and liver biopsies in patients with rheumatoid arthritis. Ann Rheum Dis. 1975;34:198–9.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009;27(6):1017–25.PubMedGoogle Scholar
  71. 71.
    Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. Sci World J. 2014;2014:823763. doi: 10.1155/2014/823763.CrossRefGoogle Scholar
  72. 72.
    Hakim NS, Kobienia B, Benedetti E, Bloomer J, Payne WD. Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int Surg. 1998;83:224–5.PubMedGoogle Scholar
  73. 73.
    Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.PubMedCrossRefGoogle Scholar
  74. 74.
    Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008;26:S39–47.PubMedGoogle Scholar
  75. 75.
    Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204–12.PubMedCrossRefGoogle Scholar
  76. 76.
    Su FH, Wu CS, Sung FC, Chang SN, Su CT, Shieh YH, et al. Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in Taiwan. PLoS One. 2014;9(11):e113579. doi: 10.1371/journal.pone.0113579.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology. 2011;50:1700–11. doi: 10.1093/rheumatology/ker190.PubMedCrossRefGoogle Scholar
  78. 78.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2. doi: 10.1002/hep.23190.PubMedCrossRefGoogle Scholar
  79. 79.
    Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:621–7. doi: 10.1007/s10165-011-0458-z.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16–23. doi: 10.1007/s10165-010-0337-z.PubMedCrossRefGoogle Scholar
  81. 81.
    Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010;12:R143. doi: 10.1186/ar3085.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Datta A, Deodhar SD, Datta U, Sehgal S. Non-organ specific & organ specific antibodies in rheumatoid arthritis. Indian J Med Res. 1990;92:228–32.PubMedGoogle Scholar
  83. 83.
    Zurgil N, Bakimer R, Moutsopoulos HM, Tzioufas AG, Youinou P, Isenberg DA, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol. 1992;12:201–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Mouritsen S, Demant E, Permin H, Wiik A. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immunol. 1986;66:68–76.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Koga T, Migita K, Miyashita T, Maeda Y, Nakamura M, Abiru S, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008;26:121–4.PubMedGoogle Scholar
  86. 86.
    Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis. 2012;2012:391567. doi: 10.1155/2012/391567.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Siegel JL, Luthra H, Donlinger J, Angulo P, Lindor K. Association of primary biliary cirrhosis and rheumatoid arthritis. J Clin Rheumatol. 2003;9:340–3.PubMedCrossRefGoogle Scholar
  88. 88.
    Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol. 1994;33:745–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjögren’s syndrome. J Hepatol. 1994;20:354–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Montaño-Loza AJ, Crispín-Acuña JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome. Ann Hepatol. 2007;6:150–5.PubMedGoogle Scholar
  91. 91.
    Tokuno T, Takahashi H, Suzuki C, Yamamoto M, Naishiro Y, Sugaya A, et al. Analysis of B-cell clonality in the hepatic tissue of patients with Sjögren’s syndrome. Scand J Rheumatol. 2003;32:268–72.PubMedCrossRefGoogle Scholar
  92. 92.
    De Santis M, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Clin Gastroenterol. 2013;27:543–51. doi: 10.1016/j.bpg.2013.06.016.Google Scholar
  93. 93.
    Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44(3):208–13. doi: 10.1097/MCG.0b013e3181c74e0d.PubMedCrossRefGoogle Scholar
  94. 94.
    Matsumoto T, Morizane T, Aoki Y, Yamasaki S, Nakajima M, Enomoto N, et al. Autoimmune hepatitis in primary Sjogren’s syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren’s syndrome. Pathol Int. 2005;55:70–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Toussirot E, Le Huédé G, Mougin C, Balblanc JC, Bettinger D, Wendling D. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren’s syndrome and hepatitis C virus infection. J Rheumatol. 2002;29:2382–5.PubMedGoogle Scholar
  96. 96.
    Esteban JI, Esteban R, Viladomiu L, López-Talavera JC, González A, Hernández JM, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989;2:294–7.PubMedCrossRefGoogle Scholar
  97. 97.
    D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–40.PubMedCrossRefGoogle Scholar
  98. 98.
    Chen J. Liver, gall and pancreas. In: Liu TH, Liu TH, Li WH, editors. Diagnostic pathology. Beijing: People Health Press; 1995. p. 242.Google Scholar
  99. 99.
    Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36:2250–6. doi: 10.3899/jrheum.090340.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Hansen BU, Eriksson S, Lindgren S. High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies. Scand J Gastroenterol. 1991;26:707–13.PubMedCrossRefGoogle Scholar
  101. 101.
    Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med. 1992;31:1348–55.PubMedCrossRefGoogle Scholar
  102. 102.
    Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388–94.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Tojo J, Ohira H, Suzuki T, Takeda I, Shoji I, Kojima T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res. 2002;22:187–95.PubMedCrossRefGoogle Scholar
  104. 104.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715.PubMedCrossRefGoogle Scholar
  105. 105.
    Shah IA, Holstege A, Riede UN. Bioptic diagnosis of Wegener’s granulomatosis in the absence of vasculitis and granulomas. Pathol Res Pract. 1984;178:407–15.PubMedCrossRefGoogle Scholar
  106. 106.
    Boissy C, Bernard E, Chazal M, Fuzibet JG, Michiels JF, Saint-Paul MC. Wegener’s granulomatosis disclosed by hepato-splenic involvement. Gastroenterol Clin Biol. 1997;21:633–5 (in French).PubMedGoogle Scholar
  107. 107.
    Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70:118–36.PubMedCrossRefGoogle Scholar
  108. 108.
    Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine. 2002;81:194–200.PubMedCrossRefGoogle Scholar
  109. 109.
    Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.PubMedCrossRefGoogle Scholar
  110. 110.
    Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, et al. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–5.PubMedCrossRefGoogle Scholar
  111. 111.
    Zhu G, Liu G, Liu Y, Xie Q, Shi G. Liver abnormalities in adult onset Still’s disease: a retrospective study of 77 Chinese patients. J Clin Rheumatol. 2009;15:284–8. doi: 10.1097/RHU.0b013e3181b57199.PubMedCrossRefGoogle Scholar
  112. 112.
    Kong XD, Xu D, Zhang W, Zhao Y, Zeng X, Zhang F. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015–9. doi: 10.1007/s10067-010-1516-1.PubMedCrossRefGoogle Scholar
  113. 113.
    Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011;41:279–85. doi: 10.1016/j.semarthrit.2010.12.006.PubMedCrossRefGoogle Scholar
  114. 114.
    Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China. Clin Rheumatol. 2012;31:175–81. doi: 10.1007/s10067-011-1798-y.PubMedCrossRefGoogle Scholar
  115. 115.
    Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–9. doi: 10.1097/MD.0000000000000021.CrossRefGoogle Scholar
  116. 116.
    Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J. Adult-onset Still’s disease: a report of 28 cases and review of the literature. Mod Rheumatol. 2008;18:480–5. doi: 10.1007/s10165-008-0104-6.PubMedCrossRefGoogle Scholar
  117. 117.
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMedGoogle Scholar
  118. 118.
    Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology. 2001;40:1398–404.PubMedCrossRefGoogle Scholar
  119. 119.
    Priori R, Barone F, Alessandri C, Colafrancesco S, McInnes IB, Pitzalis C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology. 2011;50:776–80. doi: 10.1093/rheumatology/keq397.PubMedCrossRefGoogle Scholar
  120. 120.
    Takami A, Nakao S, Miyamori H, Ooi M, Machi T, Chujo T, et al. Adult-onset Still’s disease with submassive hepatic necrosis. Intern Med. 1995;34:89–91.PubMedCrossRefGoogle Scholar
  121. 121.
    Motoo Y, Ohta H, Okai T, Sawabu N. Adult-onset Still’s disease: hepatic involvement and various serum markers relating to the disease activity. Jpn J Med. 1991;30:247–50.PubMedCrossRefGoogle Scholar
  122. 122.
    Andrès E, Kurtz JE, Perrin AE, Pflumio F, Ruellan A, Goichot B, et al. Retrospective monocentric study of 17 patients with adult Still’s disease, with special focus on liver abnormalities. Hepatogastroenterology. 2003;50:192–5.PubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  • Atsushi Takahashi
    • 1
  • Kazumichi Abe
    • 1
  • Hiroshi Watanabe
    • 1
  • Hiromasa Ohira
    • 1
  1. 1.Department of Gastroenterology and RheumatologyFukushima Medical School of MedicineFukushimaJapan

Personalised recommendations